MANAGED ENTRY SCHEMES: HYPE vs REALITY

Greg Cook, PhD.
Associate Director, Access Strategy, Policy & Capability
Bristol-Myers Squibb Australia

September 11, 2018
ISPOR Asia Pacific 2018

AGENDA

• The Growing Pressure on HTA
• MES – a Potential Solution?
• MES in Australia – History
• MES in Australia – Ipilimumab, a Case Study
• MES – Hype vs Reality & the Future
THE GROWING PRESSURE ON HTA

Payers

Patients

HTA

Industry

Regulators

THE GROWING PRESSURE ON HTA

Industry
- Non-traditional / adaptive CT programs

Traditional vs. Adaptive

Traditional Phase II and III Studies

Adaptive design - combined Phase III

Lung Cancer
Cervical Cancer
Gastrointestinal Cancer
Multiple Myelomas
Breast Cancer
Various Rare Cancers
THE GROWING PRESSURE ON HTA

Regulators - Priority reviews / combined Reg/HTA evaluations

Aligned reviews between Health Canada and HTA organizations

Patients - Demand for early access

Patient Demand for Access via Industry programs is Beginning Earlier

Patient Demand for HTA Access via Media/ Social Media is Increasing
THE GROWING PRESSURE ON HTA

Payer - Budget & Austerity Measures

Chart 1: Expenditure on pharmaceutical benefits

Clinical Uncertainty:
- Phase I/II data, single arm, surrogate endpoints, trial cross-over
- treatment algorithm, comparative effectiveness
- long-term safety

Economic Uncertainty:
- utilities, time horizon
- extrapolation method

Financial Uncertainty:
- utilization, budget

Political Uncertainty:
- health care prioritization
- fiscal situation

HTA

UNCERTAINTY
"unmeasurable risk"

RISK
"measurable uncertainty"

Growing Regulatory Conservatism: Application of the "Precautionary Principle"

"The Committee decided to cease further research until it can be proven beyond all doubt to the environment, society or public health..."
**MES – THE PANACEA?**

**Managed Entry Scheme**

*Performance Based Risk Sharing Arrangements*

**Coverage with Evidence Development**

**Managed Access Program**

• “… represent one mechanism for reducing uncertainty through greater investment in evidence collection while a technology is used within a health care system.” Garrison, Towse, Briggs et al. Value in Health 2013;16: 703-719

• “… generation of additional evidence to support the “real-world” value of promising health technologies as a condition for provisional coverage. As such, it represents a middle ground between the conventional “yes” or “no” reimbursement decisions, giving the opportunity to satisfy all parties (decision-makers, pharmaceutical companies, as well as end users).” Comparative Effectiveness Research in Health Services. Levy & Sobolev. Eds 2016

---

**MES IN AUSTRALIA - HISTORY**

• While the first example of CED in Australia was specific to bosentan for the treatment of PAH (2004), a formal mechanism for PBS reimbursement with the promise of future data was not introduced until 2011.

• Initially termed Managed Entry Scheme (MES) it is now also known as Managed Access Program (MAP).

**Table 1: Medicines identified as potential MES candidates by PBAC since introduction of formal MES policy (2011-2016)**

<table>
<thead>
<tr>
<th>Medicine</th>
<th>MES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipilimumab for metastatic melanoma (2012)</td>
<td>Pay for performance with rebates payable should 2 year OS rates in real world clinical practice in Australia not align with 2 year OS clinical trial data</td>
</tr>
<tr>
<td>Ivacaftor for cystic fibrosis (2014)</td>
<td>Pay for performance with rebates applicable for patients subsequently assessed as non-responders</td>
</tr>
<tr>
<td>Eculizumab for atypical haemolytic uraemic syndrome (2014)</td>
<td>Pay for performance with rebates applicable for patients who do not achieve an agreed clinical outcome over an agreed time period</td>
</tr>
<tr>
<td>Trametinib for metastatic melanoma (2014)</td>
<td>Pay for performance with rebates applicable should trametinib fail to deliver claimed benefits</td>
</tr>
<tr>
<td>Crizotinib for non-small cell lung cancer (2014)</td>
<td>Pay for performance with rebates applicable should crizotinib fail to deliver claimed benefits</td>
</tr>
<tr>
<td>Pembrolizumab for metastatic melanoma (2015)</td>
<td>PBS list with provision for future clinical trial evidence to support a potential price increase</td>
</tr>
<tr>
<td>Nivolumab for non-small cell lung cancer (2016)</td>
<td>PBS list with provision of future evidence to confirm effectiveness of nivolumab in NSCLC patients ≥ 75 years of age</td>
</tr>
</tbody>
</table>

The PBAC, although concerned about the cost-effectiveness of ipilimumab if the claimed survival gain were not observed in practice, recommended the listing of ipilimumab for metastatic melanoma, subject to risk-share arrangements.

**IPI MES RISK SHARE ARRANGEMENT**

- **OS at 2-years** was to be assessed in the ‘real-world’ setting for all patients initiated on ipilimumab during the first full year of PBS listing.

- Results would then be compared to the **2 year OS data** from the key ipilimumab clinical trial (23.5%)

- The sponsor to **rebate the cost of difference in performance between observed versus predicted OS benefits** of ipilimumab should observed OS be less than that seen in the key clinical trial.
RESULTS:

**Population** | **Proportion alive**
--- | ---
Clinical Trial (Hodi - 020) | 23.5%
MES - Pts registered | 23.89%
MES - Evaluable pts | 23.96%
MES - Follow-up response | 29.03%
MES - Censored patients | 34.20%

Kaplan-Meier survival estimate
CONCLUSION:
While results for this project support the use of MES to allow earlier access to innovative medicines in areas of high clinical need, it does not necessarily translate that this is the solution every time.

Indeed, as cited by Garrison et al, “It is critical for policy makers to recognise the benefits, limitations and methodological challenges in using RW data, and the need to consider carefully the costs and benefits of different forms of data collection in different situations.”


INSIGHTS & LEARNINGS - 1:

- The inherent inability of RW data to directly mirror the strong internal validity of a clinical trial is a significant risk.

- Ipilimumab MES - there was likely an initial cohort of patients that were extremely unwell due to the lack of an effective PBS listed therapy prior to ipilimumab PBS listing
  - 9.4% ECOG status of 2 or 3 vs 1.2% in CT
  - 28.9% brain metastases vs 11.4% in CT

- This negative impact on the OS numbers may have been countered by the availability of medicines not listed on the PBS and used post ipilimumab (e.g. dabrafenib, tremetinib, pembrolizumab & nivolumab) via compassionate access programs.

- Future MESs need to explicitly define the research question and factor in potential unintended consequences associated with treating patients in the RW setting.
INSIGHTS & LEARNINGS - 2:

- Setting up of the MES was both resource intensive and costly. To do so on a regular basis and across multiple jurisdictions is not seen by sponsor companies as sustainable.

- While the conditions of the program in relation to obtaining 2 year survival data were clearly stated at the time of clinician / patient enrolment, unconfirmed outcomes status was approximately 40% at the 2 year anniversary of the program. Significant effort and resources were required to gather the full set of data.

- Future MESs should establish robust and comprehensive reporting systems as a key component of the undertaking.

INSIGHTS & LEARNINGS - 3:

- While the ipilimumab MES was established as a pragmatic solution to delivering access to Australian patients in the face of data uncertainty, it was raised and implemented as a last resort option (i.e. 3rd PBAC submission ~ 2 years).

- With the recent introduction of Regulatory priority review & provisional registration in Australia discussions specific to provisional reimbursement/ MES may be better occurring prior to PBAC submissions and /or after a first-time PBAC rejection.
• Growing pressure on HTA with demand for early access to innovative medicines in the face of clinical / economic uncertainty & budgetary constraints.

• MES is one potential solution – but needs to be carefully considered on a case by case basis.

• Additional transparency from other MESs, together with learnings from the patient, clinician and payer’s perspective are needed to ensure the environmental push for earlier access to breakthrough medicines can be realised – either via MES or other means.